Malmström and colleagues 7 collected individual patient data from previous trials of BCG versus mitomycin C and performed a meta-analysis on 2,820 such data sets. After a median follow-up of 4.4 ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

In examining why banks struggle to adapt, Nasdaq and BCG found that institutions have ... risk management, oversight, analysis, and innovation. The report advocates for a fundamental mindset ...

The authorization was granted to ImmunityBio, the manufacturer of Anktiva ® (nogapendekin alfa inbakicept-pmln), an interleukin-15 receptor agonist, indicated with BCG for adult patients with BCG ...

GenAI could be India’s next trillion-dollar opportunity, transforming IT services the way cloud computing once did. But India’s ITeS sector, powering 58% of global outsourcing, faces an AI tipping ...

Rising temperature and growing threat of climate change may increase default risk in 30 per cent of agri and housing loans portfolio in the next five years, according to an analysis by BCG.

In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated they were unable to treat patients in the last 12 months due to a lack of access to TICE ® BCG. The alternative BCG source ...

With Merck & Co. largely propping up supplies of the bladder cancer-fighting bacteria Bacillus Calmette-Guérin (BCG) in the U.S., ImmunityBio has received the FDA all-clear to help pick up the ...

It offers a detailed analysis of the market from the perspectives of providers, innovators, and payers, identifying key drivers of transformation across the region. India's competitive pricing and ...